Á lódáil...
PD-L1 inhibitors in the pipeline: Promise and progress
Checkpoint inhibitors have improved survival for patients with melanoma, non-small-cell lung cancer (NSCLC), bladder, head and neck and other cancers. Antibodies against PD-L1, including atezolizumab, avelumab and durvalumab, are also being developed and have been approved for various cancers. Compa...
Na minha lista:
Foilsithe in: | Oncoimmunology |
---|---|
Main Authors: | , , , , , |
Formáid: | Artigo |
Teanga: | Inglês |
Foilsithe: |
Taylor & Francis
2017
|
Ábhair: | |
Rochtain Ar Líne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5739559/ https://ncbi.nlm.nih.gov/pubmed/29296516 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2017.1365209 |
Clibeanna: |
Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!
|